Needham Reiterates Buy on Revolution Medicines, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Revolution Medicines (NASDAQ:RVMD) and maintained a price target of $36.
November 07, 2023 | 11:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Revolution Medicines and maintained a price target of $36.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $36 price target indicates a positive outlook for Revolution Medicines. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100